Trial Profile

A phase I/IIa study to investigate the safety and clinical activity of APR-246 in combination with dabrafenib in patients with BRAF V600 mutant unresectable metastatic melanoma resistant to dabrafenib /trametinib combination

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jul 2019 Status changed from active, no longer recruiting to discontinued due to difficulty in finding patients
17 Sep 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2018.
17 Sep 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com